Literature DB >> 19262704

Preoperative chemoradiotherapy for esophageal cancer: impressive downstaging with acceptable toxicity.

Tyvin A Rich1.   

Abstract

Entities:  

Year:  2007        PMID： 19262704      PMCID： PMC2632524     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  4 in total

1.  Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.

Authors:  A A Meluch; J D Hainsworth; J R Gray; M Thomas; P L Whitworth; J L Davis; F A Greco
Journal:  Cancer J Sci Am       Date:  1999 Mar-Apr

2.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

3.  Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial.

Authors:  Anthony A Meluch; F Anthony Greco; James R Gray; Melodie Thomas; Valerie M Sutton; J Lucian Davis; Leonard A Kalman; Don W Shaffer; Kathleen Yost; David A Rinaldi; John D Hainsworth
Journal:  Cancer J       Date:  2003 Jul-Aug       Impact factor: 3.360

4.  Neoadjuvant chemoradiotherapy for esophageal cancer using weekly Paclitaxel and Carboplatin plus infusional 5-Fluorouracil.

Authors:  David E Gannett; Ron F Wolf; Gary W Takahashi; Jeannie Louie; Rick C Wagner; Fred S Ey; Michael M Owens; William E Johnson; David W Cook; Roger E Alberty
Journal:  Gastrointest Cancer Res       Date:  2007-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.